Department of Ophthalmology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.
Jpn J Ophthalmol. 2024 Jul;68(4):293-301. doi: 10.1007/s10384-024-01072-4. Epub 2024 Jul 22.
Immunoglobulin G4 (IgG4)-related disease is a clinical entity characterized by elevated serum IgG4 concentrations and infiltration of IgG4-immunopositive plasmacytes in various organs, including ophthalmic lesions. Diagnostic criteria for IgG4-related ophthalmic disease (IgG4-ROD) were established in 2014 and describe the most affected ocular adnexal tissues such as lacrimal glands, trigeminal nerves and extraocular muscles, but do not mention optic neuropathy, the most severe indication of ophthalmic lesions. We reviewed published case reports of optic neuropathy in IgG4-related disease (n = 44), and in many cases, decreased visual acuities recovered well following treatment such as systemic corticosteroids, rituximab, and orbital surgery. However, some patients did not recover, especially when pretreatment visual acuities were as low as light perception or less. Herein, we propose a 2023 revised diagnostic criteria for IgG4-ROD, which include a reminder not to overlook optic neuropathy. The 2014 diagnostic criteria specify mucosa-associated lymphoid tissue (MALT) lymphoma as an important differential diagnosis for the relationship between IgG4-ROD and orbital lymphoma. The 2023 revision directs physicians' attention toward lymphomas other than MALT lymphoma, considering that the 2014 criteria might have placed too much emphasis on MALT lymphoma.
免疫球蛋白 G4(IgG4)相关疾病是一种临床实体,其特征为血清 IgG4 浓度升高,以及 IgG4 免疫阳性浆细胞浸润到各种器官中,包括眼部病变。2014 年确立了 IgG4 相关眼病(IgG4-ROD)的诊断标准,描述了最常受影响的眼部附属组织,如泪腺、三叉神经和眼外肌,但未提及视神经病变,这是眼部病变最严重的表现。我们复习了 IgG4 相关疾病中视神经病变的已发表病例报告(n=44),在许多情况下,经全身性皮质类固醇、利妥昔单抗和眼眶手术治疗后,视力下降得到了很好的恢复。然而,一些患者没有恢复,特别是在预处理视力低至光感或更差时。在此,我们提出了 2023 年 IgG4-ROD 的修订诊断标准,其中包括提醒不要忽视视神经病变。2014 年的诊断标准将黏膜相关淋巴组织(MALT)淋巴瘤作为 IgG4-ROD 与眼眶淋巴瘤之间关系的重要鉴别诊断。2023 年的修订版提请医生注意除 MALT 淋巴瘤以外的淋巴瘤,因为 2014 年的标准可能过于强调 MALT 淋巴瘤。